At this EULAR 2022 session, one expert explains why he believes refractory gout is caused by mismanagement and discussed ways around treatment obstacles.
JAK Inhibitors: Are All Promises Fulfilled?
A decade after JAK inhibitors were approved, this EULAR 2022 session looks at whether the drugs have lived up to expectations.
How to Connect with Your Members of Congress During the August Recess
Many members of Congress return to their home states and districts in August, making it a great time to engage them in local conversations about healthcare policies and how they affect rheumatology practices and patients.
Imaging Modalities in Gout: How to Use them in Clinical Practice
This EULAR 2022 session discussed the increasing role of imaging in the diagnosis of gout.
Treating to Target in Gout: The Trouble with Serum Urate
New analyses of treat to target in gout may lead to revisions in some guidelines.
Difficult-to-Treat Lupus: When & How to Use New Therapies
Clinicians have numerous treatment options for SLE; in a EULAR 2022 session, some of the newer therapies were reviewed.
Biologic or Conventional Therapy for Early RA?
A study has shown that in untreated patients with early RA, treatment with methotrexate combined with the biologic therapies abatacept or certolizumab-pegol resulted in greater CDAI remission rates than active conventional therapy with prednisolone, sulfasalazine or hydroxychloroquine.
Phase 2 Study Shows Promising Results for Deucravacitinib in PsA
Research has demonstrated that deucravacitinib is significantly more efficacious than placebo for achieving minimal disease activity in patients with active PsA after 16 weeks of treatment.
The Rheumatologist Honored with Grand Award for Publication Excellence
We are honored to announce that The Rheumatologist has received a Grand Award for publication excellence from APEX 2022 for COVID-19: A Special Report, a supplement that mailed with the February 2021 issue of the magazine. The Annual Awards for Publication Excellence (APEX) are based on excellence in graphic design, editorial content and the ability…
Baricitinib Promising for Juvenile Idiopathic Arthritis
In a study from Ramanan et al., baricitinib proved safe and effective for reducing the time to flare and frequency of flare in patients aged 2–18 years with juvenile idiopathic arthritis.
- « Previous Page
- 1
- …
- 94
- 95
- 96
- 97
- 98
- …
- 815
- Next Page »